Aggressive Lipid Lowering Therapy for Skin Melanoma

This trial explores how aggressive lipid-lowering therapy might benefit people with melanoma who are beginning treatment with immune checkpoint inhibitors and have heart artery issues. Researchers aim to determine if lipid-lowering medications, such as Ezetimibe, PCSK9 inhibitors (alirocumab, evolocumab, inclisiran), and Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin), can improve heart health compared to usual care. Participants will undergo heart health monitoring through scans over two years to track changes. Individuals with melanoma, plaque in their heart arteries, and who are starting immune checkpoint inhibitors for the first time may find this trial suitable. As an unphased trial, this study provides a unique opportunity to enhance understanding of how lipid-lowering therapy can improve heart health in melanoma patients.

Research has shown that treatments like PCSK9 inhibitors and statins are generally well-tolerated by most people. Studies indicate that combining PCSK9 inhibitors with statins can reduce LDL cholesterol by up to 59%. This combination improves heart health without causing serious side effects for most patients.

Researchers are excited about aggressive lipid-lowering therapy for skin melanoma because it targets cholesterol levels using a combination of statins and PCSK9 inhibitors, which is a novel approach for this condition. Unlike typical melanoma treatments that focus on directly targeting cancer cells, this therapy aims to reduce LDL cholesterol to potentially influence melanoma growth indirectly. Statins and PCSK9 inhibitors, like alirocumab and evolocumab, have a unique mechanism that not only lowers LDL cholesterol but may also affect cancer cell behavior, offering a fresh angle in melanoma treatment strategies.

This trial will compare aggressive lipid-lowering therapy with usual care. Research has shown that aggressive cholesterol-lowering treatment can significantly reduce levels of LDL-C, often called "bad cholesterol." Participants in the aggressive lipid-lowering therapy arm will receive PCSK9 inhibitors along with statins, which studies have found can lower LDL-C by 55 to 76 percent. This combination also improves heart health by reducing the risk of major heart problems, such as heart attacks. Adding ezetimibe to statins can further enhance these benefits. For patients with melanoma, PCSK9 inhibitors might also lower cancer risk, making this treatment potentially beneficial in several ways.²⁶⁷⁸⁹